4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-piperazine-1-carboxylic acid tert-butyl ester | 737790-75-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-piperazine-1-carboxylic acid tert-butyl ester
• 英文别名: 4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazine-1-carboxylic acid tert-butyl ester；tert-butyl 4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinecarboxylate；tert-butyl 4-[(2R)-2-hydroxy-3-[(2-methyl-1,3-benzothiazol-5-yl)oxy]propyl]piperazine-1-carboxylate
• CAS: 737790-75-9
• 化学式: C₂₀H₂₉N₃O₄S
• 分子量: 407.534
• InChiKey: TWENMNQDGGICPL-OAHLLOKOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-piperazine-1-carboxylic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 生成 2-{4-[(R)-2-Hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}-N-p-tolyl-acetamide
  参考文献：
  名称：

  New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties

  摘要：

  New inhibitors of palmitoylCoA oxidation were synthesized based on a structurally novel lead, CVT-3501 (1). Investigation of structure-activity relationships was conducted with respect to potency of inhibition of cardiac mitochondrial palmitoylCoA oxidation and metabolic stability. Potent and metabolically stable analogues 33, 42, and 43 were evaluated in vitro for cytochrome P450 inhibition and potentially adverse electrophysiological effects. Compound 33 was also found to have favorable pharmacokinetic properties in rat. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.093
• 作为产物：
  描述：

  2-甲基-5-苯并噻唑 在 potassium carbonate 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 48.0h， 生成 4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-piperazine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties

  摘要：

  New inhibitors of palmitoylCoA oxidation were synthesized based on a structurally novel lead, CVT-3501 (1). Investigation of structure-activity relationships was conducted with respect to potency of inhibition of cardiac mitochondrial palmitoylCoA oxidation and metabolic stability. Potent and metabolically stable analogues 33, 42, and 43 were evaluated in vitro for cytochrome P450 inhibition and potentially adverse electrophysiological effects. Compound 33 was also found to have favorable pharmacokinetic properties in rat. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.093

文献信息

• [EN] 1-AKAN-2-OL SUBSTITUTED PIPERAZINE AND PIPERIDINE COMPOUNDS<br/>[FR] COMPOSES PIPERAZINE ET PIPERAZINE 1-AKAN-2-OL SUBSTITUES
  申请人：CV THERAPEUTICS INC

  公开号：WO2005061470A1

  公开（公告）日：2005-07-07

  Disclosed are novel substituted heterocyclic derivatives having the structure of Formula (I): The compounds are useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, diabetes, and myocardial infarction.

  揭示了具有以下结构的新型取代杂环衍生物（I）的化合物：这些化合物对于治疗各种疾病状态有用，特别是心血管疾病，如心房和心室心律失常，间歇性跛行，普林兹梅塔（变异）心绞痛，稳定和不稳定心绞痛，运动诱发性心绞痛，充血性心脏病，糖尿病和心肌梗死。
• [EN] UREA DERIVATIVES OF PIPERAZINES AND PIPERIDINES AS FATTY ACID OXIDATION INHIBITORS<br/>[FR] DERIVES D'UREE DE PIPERAZINES ET DE PIPERIDINES COMME INHIBITEURS DE L'OXYDATION D'ACIDES GRAS
  申请人：CV THERAPEUTICS INC

  公开号：WO2005000826A1

  公开（公告）日：2005-01-06

  Disclosed are novel piperazine derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction.

  揭示了一种新型哌嗪衍生物，可用于治疗各种疾病状态，特别是心血管疾病，如心房和心室心律失常、间歇性跛行、普林兹梅塔（变异）心绞痛、稳定和不稳定心绞痛、运动诱发性心绞痛、充血性心脏病和心肌梗死。
• [EN] SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISEASES<br/>[FR] COMPOSES HETEROCYCLIQUES SUBSTITUES UTILES POUR LE TRAITEMENT DE MALADIES CARDIO-VASCULAIRES
  申请人：CV THERAPEUTICS INC

  公开号：WO2004069818A1

  公开（公告）日：2004-08-19

  wherein: a.o. T is oxygen, sulfur, or NR11 , in which R11 is hydrogen or lower alkyl; V is -N<, -CH<, or -NH-CH<; X1 is hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; X2 is optionally substituted aryl or optionally substituted heteroaryl; Y is optionally substituted dihydroheteroarcyl; and Z1 and Z2 are independently optionally substituted alkylene of 1-4 carbon atoms, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal’s (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.

  其中：a.o. T是氧、硫或NR11，其中R11是氢或较低的烷基；V是-N<，-CH<或-NH-CH<；X1是氢，可选择取代的较低烷基，可选择取代的环烷基，可选择取代的芳基或可选择取代的杂芳基；X2是可选择取代的芳基或可选择取代的杂芳基；Y是可选择取代的二氢杂芳基；Z1和Z2分别是1-4个碳原子的可选择取代的烷基，用于治疗各种疾病状态，特别是心血管疾病，如心房和心室心律失常、间歇性跛行、普林兹梅塔（变异）心绞痛、稳定和不稳定心绞痛、运动诱发性心绞痛、充血性心脏病和心肌梗死。这些化合物还可用于治疗糖尿病。
• Substituted heterocyclic compounds
  申请人：Zablocki Jeff

  公开号：US20060052605A1

  公开（公告）日：2006-03-09

  Disclosed are novel piperazine derivatives, useful for the treatment of various disease states, in particular diseases such as atrial and ventricular arrhythmias, diabetes, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction.

  本发明涉及一种新型哌嗪衍生物，可用于治疗各种疾病状态，特别是如心房和心室心律失常、糖尿病、间歇性跛行、普林兹梅塔尔（变异型）心绞痛、稳定和不稳定性心绞痛、运动诱发性心绞痛、充血性心力衰竭和心肌梗死等疾病。
• SUBSTITUTED HETEROCYCLIC COMPOUNDS
  申请人：Elzein Elfatih

  公开号：US20080032993A1

  公开（公告）日：2008-02-07

  Disclosed are novel substituted heterocyclic derivatives having the structure of Formula I: The compounds are useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, diabetes, and myocardial infarction.

  本发明涉及新型的取代杂环衍生物，其具有公式I的结构：这些化合物可用于治疗各种疾病状态，特别是心血管疾病，如心房和心室心律失常，间歇性跛行，普林兹梅塔尔（变异性）心绞痛，稳定和不稳定性心绞痛，运动诱发性心绞痛，充血性心力衰竭，糖尿病和心肌梗塞。